Scientific Publications by FDA Staff

J Clin Microbiol 2010 Jan;48(1):281-5

HIV-Selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection.

Khurana S, Norris PJ, Busch MP, Haynes BF, Park S, Sasono P, Mlisana K, Salim AK, Hecht FM, Mulenga J, Chomba E, Hunter E, Allen S, Nemo G, Rodriguez-Chavez IR, Women's Interagency HIV Study, Joseph B. Margolick on behalf of Multicenter AIDS Cohort Study (MACS), Golding H

HIV-Selectest is a serodiagnostic enzyme immunoassay (EIA), containing p6 and gp41 peptides, designed to differentiate between vaccine-induced antibodies and true infections. A rapid test version of the HIV-Selectest was developed. Both assays detected HIV antibodies in men and women within 2 to 4 weeks of infection, with sensitivity similar to third-generation EIAs.